Table 3.

Multivariate analysis of radiogenomic signatures and clinical variables.

Clinical variables and radiogenomic signature	Prognostic assessment dataset		Prognostic testing dataset
	HR (95% CI)	Wald p value	HR (95% CI)	Wald p value
Age	0.99 (0.94–1)	0.57	0.95 (0.89–1)	0.057
ER	0.17 (0.051–0.54)	0.0028	0.31 (0.07–1.4)	0.12
PR	1.5 (0.45–4.7)	0.52	0.97 (0.21–4.5)	0.97
HER2	1.3 (0.6–2.8)	0.50	0.31 (0.086–1.1)	0.077
Tumour size	1 (1–1)	0.07	1.3 (1–1.7)	0.037
Radiogenomic signature	2.8 (1.3–5.8)	0.0067	7.7 (1.9–31)	0.0037

Statistical significance was assessed by the two-sided Wald test.

ER oestrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor, HR hazard ratio.